Clinical Trial Update: Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression [Phase 4]

View source ↗

Summary

Phase 4 trial investigating disitamab vedotin in combination with fruquintinib for metastatic colorectal cancer with HER2 expression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Fruquintinib (fruquintinib)

Snippet

Sponsor: Zhongnan Hospital | Conditions: HER2, Colorectal Cancer | Phase 4 | Status: ACTIVE_NOT_RECRUITING